HIKAL LIMITED

Hikal Limited held its Q1 FY27 earnings conference call on August 6, 2026, where management provided updates on the company's financial and operational performance for the quarter ended June 30, 2026. Management reported a revenue of Rs 403 crores and an EBITDA margin of 9.2%. The company highlighted its recent EcoVadis Gold Medal Rating, placing it in the top 5% of companies assessed for sustainability. The Pharmaceutical business showed year-on-year growth despite a planned shutdown for U.S. FDA remediation. Management noted a gradual recovery in the Crop Protection business, although pricing pressures remained due to excess supply from China. The Animal Health segment continued to perform well, with strong demand and new project validations. Management discussed ongoing investments in capacity and R&D, aiming for long-term growth across its divisions. The call concluded with management expressing confidence in the company's strategic direction and commitment to sustainable growth.

Management emphasized achievements and growth potential across various business segments.